EnGeneIC

EnGeneIC is an Australian-founded, clinical-stage biopharmaceutical company developing a first-in-class nanocell delivery platform intended to transform cancer treatment. Its core technology, the EnGeneIC Dream Vector (EDV™), is described by the company as the first bacterially derived nanocell designed to deliver precision therapy directly to the tumour while engaging the patient's own immune system. The company positions the EDV™ as a new class of cancer therapy that combines cancer cell killing with immune cell activation — a "cyto-immunotherapy" approach. The EDV™ platform is built around robust, uniform empty nanocells roughly 400 nanometres in diameter, harvested from avirulent, non-pathogenic bacteria. Potent chemotherapy, functional nucleic acids, or immune adjuvants are loaded into separate EDVs. An antibody is then attached to the nanocell wall; one arm binds the nanocell while the other recognises a chosen tumour antigen such as EGFR. The targeted EDVs are administered by intravenous infusion over five to ten minutes, escape into the tumour microenvironment through leaky tumour blood vessels, and bind to cancer cells via the antibody, triggering engulfment and cell death. Meanwhile, immune cells such as macrophages, dendritic cells and natural killer cells take up EDVs, recognise their bacterial origin, and are stimulated into an activated state. EnGeneIC's origins are rooted in a promise. In the late 1990s, founders Dr Jennifer MacDiarmid and Dr Himanshu Brahmbhatt were vaccine researchers at CSIRO when a skilled laboratory technician, Kin San Lee, collapsed at the bench and was diagnosed with terminal lung cancer. Before his death he urged them to do something about cancer. They began working nights on cancer research, and that partnership set out to succeed where conventional treatment could not. The company frames its mission around the limitations of conventional cancer care — surgery, radiation and chemotherapy — noting that chemotherapy affects the whole body, damages healthy cells, causes significant side-effects, and can lead to drug resistance. EnGeneIC argues that the central challenge is not only which drugs are used but how they are delivered. The company is headquartered in Lane Cove West, New South Wales, Australia, and operates as a private, clinical-stage enterprise. Its pipeline activity has extended into the United States, where it has reported clinical milestones in recurrent glioblastoma. In 2026 the company announced it had dosed its first patient with a novel EGFR-targeted nanocell therapy for recurrent glioblastoma, and it was honoured with a Breakthrough in Glioblastoma Biotech Award at a Northwell Foundation Lenox Hill Neurosurgery brain cancer gala in New York. EnGeneIC continues to develop the EDV™ nanocell as a platform that can carry different payloads and target different antigens, positioning it as a programmable delivery system for precision oncology.

EnGeneIC is an Australian-founded, clinical-stage biopharmaceutical company whose story began in the late 1990s. Its founders, Dr Jennifer MacDiarmid and Dr Himanshu Brahmbhatt, were vaccine researchers at CSIRO, Australia's national science agency, when a skilled laboratory technician named Kin San Lee collapsed at the bench and was diagnosed with terminal lung cancer. Shortly before his death, Lee told them: "If anybody can do something about cancer, you can. So go and do it." That promise became the founding impulse of the company. MacDiarmid and Brahmbhatt began working nights on cancer research, forging a partnership built on the ambition to succeed where conventional treatment could not. The company's central insight was that the enduring challenge of oncology lies not only in which drugs are used but in how they are delivered. For decades, cancer treatment had relied on surgery, radiation and chemotherapy. Chemotherapy, while important, affects the whole body, damaging healthy cells alongside cancer cells and causing significant side-effects; repeated treatment can weaken patients and allow cancers to develop drug resistance. Many patients cycle through multiple therapies until options run out, with a heavy toll on quality of life. EnGeneIC set out to rethink drug delivery at its most fundamental level. The result was the EDV™ platform — the EnGeneIC Dream Vector — inspired by naturally occurring bacterial vesicles and their ability to deliver payloads. The EDV™ nanocell is described as a first-in-class cyto-immunotherapy platform: the first bacterially derived nanocell designed to deliver precision therapy directly to the tumour and engage the patient's own immune system. The technology uses robust, uniform empty nanocells roughly 400 nanometres in diameter, harvested from avirulent, non-pathogenic bacteria. Potent chemotherapy, functional nucleic acids, or immune adjuvants are loaded into separate EDVs. An antibody is attached to the nanocell wall so that one arm binds the nanocell and the other recognises a tumour antigen such as EGFR. Administered by intravenous infusion over five to ten minutes, the targeted EDVs escape into the tumour microenvironment through leaky tumour blood vessels, bind to cancer cells via the antibody, and trigger engulfment and cell death. At the same time, immune cells including macrophages, dendritic cells and natural killer cells take up EDVs, recognise their bacterial origin, and are stimulated into action — combining direct tumour killing with immune activation. EnGeneIC is headquartered in Lane Cove West, New South Wales, Australia, and operates as a private, clinical-stage biopharmaceutical company. Its clinical development has reached the United States. In April 2026 the company announced it had dosed the first patient with a novel EGFR-targeted nanocell therapy for recurrent glioblastoma. In July 2026 it was honoured with the 2026 Breakthrough in Glioblastoma Biotech Award at the Northwell Foundation Lenox Hill Neurosurgery Brain Cancer Gala in New York. The company continues to develop the EDV™ nanocell as a programmable platform capable of carrying different payloads and targeting different antigens, positioning it as a new class of cancer therapy for precision oncology.

• Founders Dr Jennifer MacDiarmid and Dr Himanshu Brahmbhatt begin working nights on cancer research at CSIRO after a promise to dying colleague Kin San Lee.

• EnGeneIC founded in Australia as a clinical-stage biopharmaceutical company developing the EDV™ nanocell platform.

• EnGeneIC doses first patient with novel EGFR-targeted nanocell therapy for recurrent glioblastoma.

• EnGeneIC honored with 2026 Breakthrough in Glioblastoma Biotech Award at Northwell Foundation Lenox Hill Neurosurgery Brain Cancer Gala in New York.

First-in-class bacterially derived nanocell platform delivering precision therapy directly to the tumour while engaging the patient's own immune system.

• EDV™ nanocell platform

  First-in-class cyto-immunotherapy platform using bacterially derived nanocells ~400 nm in diameter to deliver precision therapy to tumours and engage the immune system.

• EGFR-targeted nanocell therapy

  EDVs loaded with a potent chemotherapy payload and coated with an antibody that binds EGFR on tumour cells; administered by IV infusion.

1. 1EnGeneIC | Precision EDV™ Nanocell Cancer Therapiesengeneic.com
2. 2About EnGeneIC | Pioneers of EDV™ Nanocell Therapyengeneic.com
3. 3Engeneic (Australia) - Wikidatawikidata.org